USPTO Patent Applications - Therapeutics (A61P)

Glutathione Trisulfide Patent for Chemotherapy-Induced Neuropathy

Glutathione Trisulfide Patent for Chemotherapy-Induced Neuropathy

Heterotrophic Skin Bacteria Composition for Treating UV Damage and PLE

The USPTO published patent application US20260097086A1 by inventor Catherine O'Neill for a composition comprising heterotrophic skin bacteria or bacterial extract for modulating cytokine expression in skin cells. The composition is intended for preventing and treating skin damage caused by UV light and for treating polymorphous light eruption (PLE).

Cbfβ-Expressing Vascular Smooth Muscle Cells for Age-Related Disease Treatment

The USPTO published patent application US20260097084A1 by Kyungpook National University Industry-Academic Cooperation Foundation covering a pharmaceutical composition containing Cbfβ-expressing vascular smooth muscle cells or culture fluid for preventing or treating age-related diseases. The invention demonstrates that Cbfβ expression in vascular smooth muscle cells inhibits osteoclast differentiation and prevents vascular calcification, offering potential therapeutic applications for conditions such as osteoporosis and age-related vascular disorders.

Pharmaceutical Composition Containing Neonatal Pig-Derived Mesenchymal Stem Cells for Treating Non-Porcine Animals

USPTO published patent application US20260097081A1 by Fukuoka University for a pharmaceutical composition containing neonatal pig-derived mesenchymal stem cells. The cells produce at least one humoral factor selected from TGF-β1, TGF-β2, VEGF-A, and VEGF-C for therapeutic use in treating cardiovascular conditions, wounds, and decubitus in non-porcine animals. The application was filed on October 10, 2025.

Engineered Immune Cells CAR-T CAR-NK BCMA TACI Cancer Therapy Patent Application

USPTO published patent application US20260097076A1 for engineered immune cells (T cells and NK cells) expressing chimeric antigen receptors targeting BCMA and/or TACI antigens for cancer therapy. The application discloses armored CAR-T and CAR-NK cells with enhanced features for tumor treatment. Filed September 20, 2023, by inventors Chen, Agrahari, Zhao, Nguyen, Zhang, Jiang, and O'Callaghan.

Ammonium Chloride Formulations for Viral Defense

The USPTO published patent application US20260097072A1 for ammonium chloride formulations designed to support human natural defense against viral infections. The invention claims compositions and methods using lysosomotropic agents, such as ammonium chloride (NH4Cl), to prevent viral uncoating within lysosomes of infected cells. The patent names Nikolaos Tsirikos-Karapanos and Nikolaos Drakoulis as inventors.

PTGS2 Skin Disorders Carnosine Compound Treatment Method

USPTO published patent application US20260096978A1 disclosing a method for preventing, mitigating, or treating PTGS2-induced skin disorders using carnosine compounds of formula (I) applied to human skin. The application, filed November 14, 2022, names five inventors and covers cosmetic and dermatological formulations.

Human Hair Follicle-Derived Conditioned Media and Method of Making Same

USPTO published patent application US20260097082A1 covering methods for preparing hair follicle-derived conditioned media containing bioactive factors. The hair follicles are retrieved non-invasively and cultured to secrete therapeutic compounds. The application covers compositions for therapeutic and cosmetic treatments including hair restoration and skin repair.

Markers for the Diagnosis of Biochemical Recurrence in Prostate Cancer

USPTO published patent application US20260092922A1 for biomarkers and diagnostic methods related to prostate cancer biochemical recurrence (BCR). The application (No. 19207308, filed May 13, 2025) includes 9 inventors and covers methods for detecting BCR biomarkers, compositions, and diagnostic kits. This is a routine patent publication with no new regulatory requirements.

Multivalent FZD4, Wnt Co-receptor, and VEGF Binding Molecules

EyeBiotech Limited published US Patent Application US20260092125A1 for multivalent antibody binding molecules comprising FZD4 receptor binding, LRP5 co-receptor binding, and VEGF binding domains that activate the Wnt/β-catenin signaling pathway. The application covers the molecules, nucleic acids, vectors encoding them, and methods of use. Inventors include Paul E. Stephens, Michael John Davies, Yin Shan Eric Ng, Masahisa Handa, and Alexander V. Loktev. The application was filed September 4, 2025, and published April 2, 2026.

Anti-NRP2 Antibody Compositions and Methods for Treating NRP2-Associated Diseases

The USPTO published patent application US20260092122A1 for affinity-matured and humanized antibodies targeting human neuropilin-2 (NRP2) polypeptides. The application (No. 19293892, filed August 7, 2025) names six inventors and covers therapeutic compositions and methods for modulating NRP2 activity to treat NRP2-associated diseases, including cancer (A61P 35/04).

Treatment of Cancer Using Anti-HLA-G/Anti-CD3 Bispecific Antibody and 4-1BB Agonist

The USPTO published patent application US20260092118A1 by Hoffmann-La Roche Inc., covering a method for treating cancer using an anti-HLA-G/anti-CD3 bispecific antibody in combination with a 4-1BB (CD137) agonist. The application (No. 19325175) was filed September 10, 2025, and lists Meher Majety, Carina Hage, and Johannes Sam as inventors. This publication represents an early-stage intellectual property filing for a bispecific antibody-based cancer therapy.

Bladder Cancer Classification and Treatment Using Atezolizumab

The USPTO published patent application US20260092117A1 disclosing methods for classifying and treating bladder cancer (including locally advanced or metastatic urothelial cancer) using atezolizumab, a PD-1 axis binding antagonist. The application covers diagnostic methods, treatment regimens, compositions, kits, and articles of manufacture for bladder cancer classification and therapy. The application was filed on April 4, 2025.

B7H3/PDL1 Bispecific Antibody Cancer Therapeutic

The USPTO published patent application US20260092116A1 by DARTSBIO Pharmaceuticals Ltd. covering a B7H3/PDL1 bispecific antibody for cancer treatment. The invention comprises a monoclonal antibody targeting PDL1 linked to nano-antibodies targeting B7H3, designed to relieve T-cell inhibition while targeting tumor cells. The application was filed October 13, 2022, with six inventors.

Anti-CTLA-4 antibodies with variant Fc regions

The USPTO published patent application US20260092115A1 for anti-CTLA-4 antibodies featuring variant Fc regions and methods of production and use. The application (No. 19407391) was filed December 3, 2025, by a team of 11 inventors including researchers from pharmaceutical companies. The invention relates to therapeutic antibodies modified to enhance effector functions through Fc region engineering.

Treatment of Lung Cancer Using Anti-PD-1 Antibody Combination

The USPTO published Bristol-Myers Squibb Company's patent application (US20260092114A1) for a method of treating lung cancer using a combination of an anti-PD-1 antibody administered by infusion in under 60 minutes and optionally an anti-CTLA-4 antibody administered in under 90 minutes. The application was filed on September 29, 2025.

CD28/OX40 Bispecific Antibodies for Solid Organ Transplant Rejection Treatment

The USPTO published patent application US20260092113A1, filed by Bristol-Myers Squibb, covering methods for treating solid organ transplant rejection using CD28/OX40 bispecific antibodies. The application (No. 19237572) claims a multispecific binding protein with a VHH domain targeting CD28 and a VH/VL domain targeting OX40. Inventors include Rami Lissilaa, Benjamin Suratt, and Jessica Voss.

Anti-CTLA-4 Antibodies for Treating Adenoid Cystic Carcinoma

The USPTO published patent application US20260092112A1 covering uses of anti-CTLA-4 antibodies for treating adenoid cystic carcinoma. Inventors Yang Liu and Pan Zheng filed Application No. 19112015 on September 15, 2023, with the application published April 2, 2026. The invention claims therapeutic applications of anti-CTLA-4 antibodies specifically for adenoid cystic carcinoma.

TREM2 antibodies patent, neurodegenerative disease treatment, 2nd Apr

TREM2 antibodies patent, neurodegenerative disease treatment, 2nd Apr

Treatment of Acute Cannabinoid Overdose

USPTO published patent application US20260091020A1 for methods of treating acute cannabinoid intoxication and metrics for evaluating cannabis intoxication. Inventors are Joseph Fenton LAWLER, Daniel Pawel SCHNEEBERGER, and Kenneth C. CUNDY, with application filing date of September 25, 2023.

Panobinostat Combination Therapy for Cholangiocarcinoma Treatment

The USPTO published patent application US20260091021A1 covering combination therapies comprising panobinostat for treating cholangiocarcinoma. The application (No. 19413668, filed December 9, 2025) names seven inventors and claims pharmaceutical compositions combining panobinostat with cytotoxic agents.

Treatments for Inflammation - Connexin Hemichannel Modulators

USPTO published patent application US20260091017A1 by inventors Shome, Mugisho, and Rupenthal for inflammation treatment compounds and methods using connexin hemichannel modulators, inflammasome modulators, and pannexin channel modulators. The application covers compositions for treating ocular and dermatological diseases characterized by inflammasome-mediated inflammation through systemic and topical administration. Application No. 19342361 filed September 26, 2025.

Patent for micheliolide compositions to increase muscle mass

USPTO published patent application US20260091019A1 by Korea Institute of Science and Technology for a pharmaceutical composition containing micheliolide as an active ingredient for increasing muscle mass, improving muscle function, or preventing or treating muscular disease. The application (No. 19302634) was filed August 18, 2025 and published April 2, 2026, listing 12 inventors including Myungsuk Kim and Choong-Gu Lee.

Chrysin Pinocembrin CAPE Composition for Neuroinflammation Prevention

The USPTO published patent application US20260091016A1 claiming a composition comprising chrysin, pinocembrin, and CAPE (caffeic acid phenethyl ester) for preventing or treating neuroinflammation and associated neuropsychiatric and neurological diseases. Application No. 18904297 was filed October 2, 2024. The composition is classified under CPC codes A61K 31/352, A61K 31/216, A61K 35/644, and A61P 25/28.

Multifunctional drug delivery system for cancer treatment antibodies

USPTO published patent application US20260091125A1 for a multifunctional drug delivery system using inorganic core particles conjugated to antibodies for cancer treatment. The system delivers distinct immunoglobulins to cancerous cells and tissues outside the brain via four-linker architecture. Application filed January 12, 2023; granted Application No. 18865714.

Janus antimicrobial nanoparticles embedded in polymers

USPTO published patent application US20260091127A1 for Janus antimicrobial nanoparticles with distinct hydrophobic and polycationic surfaces embedded in crosslinked polymers. The invention aims to enhance traditional antibiotics and reduce necessary dosages against multi-drug resistant bacteria. Application No. 19344327 was filed September 29, 2025, and published April 2, 2026.

BacPROTACs for Targeted Protein Degradation in Bacteria

Washington University published patent application US20260091118A1 for bivalent agents (BacPROTACs) designed for targeted protein degradation in mycobacteria and other bacteria, including methods for reducing antibiotic resistance. The application (No. 19312129, filed August 27, 2025) covers compositions and methods for treating antibiotic-resistant bacterial infections.

Coronavirus Vaccine Nucleic Acid LNP Patent

USPTO published CureVac SE's patent application (US20260091107A1) for nucleic acid sequences and compositions suitable for coronavirus vaccines, particularly COVID-19, delivered via lipid nanoparticle (LNP) technology. The application covers compositions, vaccines, first and second medical uses, and methods of treatment or prevention. Filed as Application No. 19317057 with priority date September 2, 2025.

Macrophage targeting drug conjugates with mannose linker

The USPTO published patent application US20260091117A1 for macrophage targeting drug conjugates developed by P.I.F. Entrepreneurs Ltd. The conjugates comprise a drug moiety, mannose moiety, and linker (hydrazone or oxime group) for targeted therapeutic delivery. Application No. 19411275 was filed December 7, 2025.

Targeted Delivery System Using CD45+ Leukocyte Cells for Glioma Treatment

USPTO published patent application US20260091119A1 disclosing an isolated targeted delivery system using CD45+ leukocyte cells containing iron binding proteins complexed with therapeutic or diagnostic agents for glioma treatment. Inventors include Magdalena KRÓL and seven co-inventors. The application was filed on September 1, 2023.

Anti-B7-H3 ADC Combined with ATR/ATM Inhibitor for Cancer Treatment

The USPTO published patent application US20260091123A1 by Daiichi Sankyo Company Limited covering a pharmaceutical composition and method of treatment combining an anti-B7-H3 antibody-drug conjugate with an ATR inhibitor or ATM inhibitor for cancer therapy. The application claims the drug-linker conjugate structure and treatment methods. Filing date was October 9, 2025.

Mycobacterium Vaccine Compositions for Immune System Modulation

The USPTO published patent application US20260091098A1 by inventor Bruce S. Gillis covering methods and compositions using killed or inactivated Mycobacterium or antigenic fragments for modulating immune system function. The application was filed September 12, 2025, under Application No. 19327636. This is a published patent application and does not grant any rights or impose obligations on third parties at this time.

BabA Antibodies for Preventing H. pylori Gastric Disease

USPTO published patent application US20260091099A1 by inventors Borén and Hammarström covering recombinant blood group antigen-binding adhesin (BabA) compositions that raise antibodies targeting conserved epitopes in the Leb antigen binding domain of BabA. The application discloses methods for preventing H. pylori-associated gastric diseases including gastric cancer, peptic ulcers, and gastritis without eradicating the infection.

Methods Of Treating Plantar Fibromatosis

The USPTO published patent application US20260091093A1 disclosing methods of treating plantar fibromatosis. The application (No. 19288249) was filed August 1, 2025, and names five inventors including James P. Tursi and Jeffrey David Lehrman. The invention relates to therapeutic methods using compositions classified under A61K 38/4886.

Tick Immunity Compositions and Methods

USPTO published patent application US20260091095A1 by inventors Erol Fikrig and Sukanya Narasimhan for compositions and methods generating tick immunity. The application (No. 19320550) was filed September 5, 2025, and published April 2, 2026. The invention covers pharmaceutical compositions for tick immunity under CPC classifications A61K 39/0003, A61P 33/14, and related subclasses.

Halogenated Phenol Antimicrobial Composition

The USPTO published patent application US20260091002A1 filed by Industry Academic Cooperation Foundation of Yeungnam University for a halogenated phenol derivative composition with antimicrobial and antibiofilm activity against Staphylococcus aureus and pathogenic microorganisms. The application, filed June 10, 2025, covers the composition, methods of use, and treatment of biofilm-related infections.

P55gamma as Therapeutic Target for Aortic Dissection

The USPTO published patent application US20260091091A1 claiming p55γ as a therapeutic target for aortic dissection (AD). The inventors from China demonstrated that p55γ overexpression inhibits AD formation and elastic fiber degradation in β-aminopropionitrile fumarate (BAPN)-induced mouse models. The patent covers using p55γ as a screening target for drugs to prevent and/or treat AD.

Incretin analog tri-receptor agonist compositions for weekly dosing

USPTO published patent application US20260091087A1 disclosing dosing regimens and compositions for long-acting incretin analog tri-receptor agonists targeting GIP, GLP-1, and glucagon receptors for once-weekly administration. The application (No. 19393199) was filed November 18, 2025, and names Tamer Coskun, Zvonko Milicevic, and Shweta Urva as inventors.

Incretin Analog Dosing and Composition Methods for GLP-1 GIP GCG Tri-Agonists

The USPTO published patent application US20260091088A1 disclosing dosing regimens and compositions for long-acting incretin analogs comprising glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon (GCG) tri-receptor agonists suitable for once-weekly administration. The application covers methods for treating metabolic conditions including obesity (A61P 3/04) and diabetes (A61P 3/10).

4-Hexylresorcinol pharmaceutical composition for bone disease treatment

The USPTO published patent application US20260091001A1 filed by Kyungpook National University Industry-Academic Cooperation Foundation for a pharmaceutical composition comprising 4-hexylresorcinol (4-HR) as an active ingredient for the prevention or treatment of bone diseases, including osteoporosis. The application claims formulations including ointments that demonstrated improved bone thickness, density, and strength in osteoporosis-induced animal models by promoting osteoblast differentiation and suppressing osteoclast proliferation.

Methods Of Treating Plantar Fibromatosis

The USPTO published patent application US20260091092A1 on April 2, 2026, disclosing methods of treating plantar fibromatosis. The application (No. 19288073) was filed August 1, 2025, with inventors James P. Tursi, Luis A. Ortega, Qinfang Xiang, Saji Vijayan, Jeffrey David Lehrman, and David Hernandez. The patent covers therapeutic approaches using compounds classified under A61K 38/4886 and A61K 9/0019.

Orodispersible Estetrol Dosage Unit Patent

USPTO published patent application US20260090995A1 by ESTETRA SRL covering an orodispersible solid pharmaceutical dosage unit containing estetrol particles (0.1-25 wt.%) for sublingual, buccal, or sublabial administration. The dosage unit weighs 30-1,000 mg, contains at least 100 μg of estetrol component, and is manufactured via wet granulation of particles sized 2-50 μm. Application No. 19340502 was filed September 25, 2025.

Cat Food Composition for Treating or Preventing Urolithiasis

The USPTO published patent application US20260090570A1 for a cat food composition designed to treat or prevent urolithiasis (urinary stones) in cats. The wet and dry compositions include omega-3 fatty acids from flaxseed and fish oil, along with pH-modifying ingredients such as calcium sulfate, methionine, sodium acid pyrophosphate, taurine, and potassium sulfate. The application was filed on October 1, 2024, under application number 18903721.

Polymer Nanoparticle Compositions for NF1 Treatment

The USPTO published patent application US20260090998A1 covering methods of using block copolymer nanoparticles for delivering nucleic acids to treat Neurofibromatosis Type 1 (NF1). The application (filed October 2, 2025) names 12 inventors and discloses compositions and methods for in vivo therapeutic delivery using polymer nanoparticles.

Delayed Release IBD Treatment Composition

Aihol Corporation filed patent application US20260090996A1 for a delayed-release oral pharmaceutical composition containing mesalamine and hyaluronan layers for treating inflammatory bowel disease. The USPTO published the application on April 2, 2026, with Application No. 19399068 and a filing date of November 24, 2025. This patent covers novel multi-layer coating technology for targeted drug delivery to the colon.

Cannabinoid Emulsion Compositions for Treating Ophthalmic Conditions

Rhodes Technologies published patent application US20260090988A1 for stable cannabinoid emulsion compositions designed for ocular delivery to treat ophthalmic conditions including glaucoma. The application, filed July 29, 2025, and published April 2, 2026, names inventors Ping Chang, Zhenze Hu, and Yuanyuan Tao. This publication represents a patent application only and does not grant enforceable patent rights.

Aspirin Oral Mucosal Formulations

USPTO published patent application US20260090985A1 for oral mucosal aspirin formulations (91-200mg micronized) with buffer and surfactant components. The application, filed by inventor James Dzandu, covers sublingual and buccal delivery formulations with pH ≤3. No regulatory obligations or compliance deadlines are imposed by this patent publication.

LifeActive Transdermal Delivery Formulations Patent Application

USPTO published patent application US20260090982A1 for LifeActive, Inc., covering transdermal delivery formulations for therapeutic agents, drugs, and nutrients. Inventors include Calvin Dexter Morris, Burgess A. Thomasson Jr., and Scott A. Jenkins. The application discloses homogeneous transdermal formulations combining weak organic acid accelerants with fatty acid microemulsions for enhanced skin absorption.

Urolithin oral care compositions patent application

USPTO published patent application US20260090966A1 for urolithin-based oral care compositions including toothpaste, mouthwash, gels, and chewing gum with therapeutic or cosmetic effects. The application covers compositions comprising urolithins, methods of treatment, and formulations with additional active ingredients such as fluoride. Inventors include Christopher L. Rinsch, Davide D'Amico, Anurag Singh, and Charlotte Tissot.

Cat Food Composition for Treating Urolithiasis and Reducing Hairballs

The USPTO published patent application US20260090571A1 for a cat food composition targeting urolithiasis (urinary stones) and hairball reduction. Inventors Nolan Z. Frantz, Angela M. Gajda, and Todd Harper developed wet and dry formulations incorporating omega-3 sources (flaxseed, fish oil), acidifiers (calcium sulfate, SAPP), methionine, taurine, and dietary fiber to achieve urine pH between 6.15-6.85 and reduce RSS struvite to ≤1.8 and RSS oxalate to ≤6.0.